{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T03:30:08Z","timestamp":1771299008681,"version":"3.50.1"},"reference-count":34,"publisher":"Harborside Press, LLC","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:p><jats:italic>HER2<\/jats:italic> mutations have been shown to be targetable in select cases of salivary gland cancers with overexpression or amplification of the <jats:italic>HER2<\/jats:italic> oncogene. Fam-trastuzumab deruxtecan, a novel antibody\u2013drug conjugate that combines trastuzumab with a topoisomerase I inhibitor, has recently demonstrated efficacy as a third-line agent in HER2-overexpressing breast cancer after trastuzumab failure. These promising results in breast cancer suggest a potential paradigm for use in other tumors with known <jats:italic>HER2<\/jats:italic> alterations, including salivary gland cancer. This report describes a 67-year-old man with HER2-positive metastatic parotid gland carcinoma who experienced disease progression after parotidectomy with adjuvant cisplatin-based chemoradiation, neratinib, and ado-trastuzumab emtansine. After disease progression on the latter HER2-directed therapy, his malignancy demonstrated complete response to fam-trastuzumab deruxtecan, which has been sustained for the past 7 months. Fam-trastuzumab deruxtecan appears to be a well-tolerated therapeutic option in patients with HER2-positive salivary gland carcinoma, with activity demonstrated after progression on ado-trastuzumab emtansine and HER2-directed kinase inhibition. Further studies should be conducted to explore the use of this agent in HER2-positive salivary gland cancers.<\/jats:p>","DOI":"10.6004\/jnccn.2021.7089","type":"journal-article","created":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T20:23:55Z","timestamp":1644265435000},"page":"102-104","source":"Crossref","is-referenced-by-count":7,"title":["Metastatic Parotid Gland Carcinoma With ERBB2 Amplification With Complete Response to Fam\u2010Trastuzumab Deruxtecan"],"prefix":"10.6004","volume":"20","author":[{"given":"Navika D.","family":"Shukla","sequence":"first","affiliation":[{"name":"1Stanford University School of Medicine; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan S.","family":"Chiang","sequence":"additional","affiliation":[{"name":"2Department of Medicine, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander D.","family":"Colevas","sequence":"additional","affiliation":[{"name":"3Division of Medical Oncology, Department of Medicine, Stanford University Medical Center, Stanford, California."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4047","reference":[{"key":"ref291","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1002\/ijc.30870","article-title":"DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance","volume":"141","author":"Takegawa","year":"2017","journal-title":"Int J Cancer"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S1470-2045(19)30088-9","article-title":"Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study","volume":"20","author":"Shitara","year":"2019","journal-title":"Lancet Oncol"},{"key":"ref01","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/S1368-8375(03)00097-6","article-title":"Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study","volume":"39","author":"Haddad","year":"2003","journal-title":"Oral Oncol"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.annonc.2019.11.018","article-title":"Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study","volume":"31","author":"Kurzrock","year":"2020","journal-title":"Ann Oncol"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41416-019-0635-y","article-title":"Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer","volume":"122","author":"Hunter","year":"2020","journal-title":"Br J Cancer"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"288","DOI":"10.6004\/jnccn.2015.0040","article-title":"Abiraterone in metastatic salivary duct carcinoma","volume":"13","author":"Urban","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"102069","DOI":"10.1016\/j.ctrv.2020.102069","article-title":"Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: a systematic review","volume":"89","author":"Uijen","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.annonc.2019.11.018","article-title":"Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study","volume":"31","author":"Kurzrock","year":"2020","journal-title":"Ann Oncol"},{"key":"ref281","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1093\/annonc\/mdz291","article-title":"Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric\/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q","volume":"30","author":"Jhaveri","year":"2019","journal-title":"Ann Oncol"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N Engl J Med"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1093\/annonc\/mdz291","article-title":"Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric\/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q","volume":"30","author":"Jhaveri","year":"2019","journal-title":"Ann Oncol"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S1470-2045(19)30088-9","article-title":"Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study","volume":"20","author":"Shitara","year":"2019","journal-title":"Lancet Oncol"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1002\/ijc.30870","article-title":"DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance","volume":"141","author":"Takegawa","year":"2017","journal-title":"Int J Cancer"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/hed.25035","article-title":"Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: a nationwide case series of 35 patients in The Netherlands","volume":"40","author":"Boon","year":"2018","journal-title":"Head Neck"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.path.2020.10.001","article-title":"Genomic analysis of salivary gland cancer and treatment of salivary gland cancers","volume":"14","author":"Palsgrove","year":"2021","journal-title":"Surg Pathol Clin"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"4623","DOI":"10.1158\/1078-0432.CCR-16-0637","article-title":"Comprehensive molecular characterization of salivary duct carcinoma reveals actionable targets and similarity to apocrine breast cancer","volume":"22","author":"Dalin","year":"2016","journal-title":"Clin Cancer Res"},{"key":"ref331","doi-asserted-by":"crossref","first-page":"288","DOI":"10.6004\/jnccn.2015.0040","article-title":"Abiraterone in metastatic salivary duct carcinoma","volume":"13","author":"Urban","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1158\/1078-0432.CCR-03-0253","article-title":"HER2 expression in salivary gland carcinomas: dependence on histological subtype","volume":"10","author":"Glisson","year":"2004","journal-title":"Clin Cancer Res"},{"key":"ref101","article-title":"Ado-trastuzumab emtansine in patients with HER2 amplified salivary gland cancers (SGCs): results from a phase II basket trial [abstract]","volume":"37","author":"Li","year":"2019","journal-title":"J Clin Oncol"},{"key":"ref231","doi-asserted-by":"crossref","first-page":"4623","DOI":"10.1158\/1078-0432.CCR-16-0637","article-title":"Comprehensive molecular characterization of salivary duct carcinoma reveals actionable targets and similarity to apocrine breast cancer","volume":"22","author":"Dalin","year":"2016","journal-title":"Clin Cancer Res"},{"key":"ref301","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41416-019-0635-y","article-title":"Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer","volume":"122","author":"Hunter","year":"2020","journal-title":"Br J Cancer"},{"key":"ref271","article-title":"Ado-trastuzumab emtansine in patients with HER2 amplified salivary gland cancers (SGCs): results from a phase II basket trial [abstract]","volume":"37","author":"Li","year":"2019","journal-title":"J Clin Oncol"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.path.2020.10.001","article-title":"Genomic analysis of salivary gland cancer and treatment of salivary gland cancers","volume":"14","author":"Palsgrove","year":"2021","journal-title":"Surg Pathol Clin"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/S1368-8375(03)00097-6","article-title":"Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study","volume":"39","author":"Haddad","year":"2003","journal-title":"Oral Oncol"},{"key":"ref251","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N Engl J Med"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/hed.25035","article-title":"Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: a nationwide case series of 35 patients in The Netherlands","volume":"40","author":"Boon","year":"2018","journal-title":"Head Neck"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1158\/1078-0432.CCR-03-0253","article-title":"HER2 expression in salivary gland carcinomas: dependence on histological subtype","volume":"10","author":"Glisson","year":"2004","journal-title":"Clin Cancer Res"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1002\/hed.23940","article-title":"Clinical activity of androgen deprivation therapy in patients with metastatic\/relapsed androgen receptor-positive salivary gland cancers","volume":"38","author":"Locati","year":"2016","journal-title":"Head Neck"},{"key":"ref321","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1002\/hed.23940","article-title":"Clinical activity of androgen deprivation therapy in patients with metastatic\/relapsed androgen receptor-positive salivary gland cancers","volume":"38","author":"Locati","year":"2016","journal-title":"Head Neck"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"102069","DOI":"10.1016\/j.ctrv.2020.102069","article-title":"Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: a systematic review","volume":"89","author":"Uijen","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.oraloncology.2009.05.635","article-title":"Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs)","volume":"45","author":"Locati","year":"2009","journal-title":"Oral Oncol"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.oraloncology.2009.05.635","article-title":"Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs)","volume":"45","author":"Locati","year":"2009","journal-title":"Oral Oncol"},{"key":"ref261","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1158\/2159-8290.CD-19-1014","article-title":"Targeting HER2 with trastuzumab deruxtecan: a dose-expansion, phase I study in multiple advanced solid tumors","volume":"10","author":"Tsurutani","year":"2020","journal-title":"Cancer Discov"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1158\/2159-8290.CD-19-1014","article-title":"Targeting HER2 with trastuzumab deruxtecan: a dose-expansion, phase I study in multiple advanced solid tumors","volume":"10","author":"Tsurutani","year":"2020","journal-title":"Cancer Discov"}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/20\/2\/article-p102.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/20\/2\/article-p102.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T18:34:55Z","timestamp":1644604495000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/20\/2\/article-p102.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":34,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2021.7089","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2]]}}}